Spyre Therapeutics, Inc. (SYRE)
NASDAQ: SYRE · Real-Time Price · USD
22.24
+0.05 (0.23%)
At close: Oct 16, 2025, 4:00 PM EDT
22.15
-0.09 (-0.40%)
After-hours: Oct 16, 2025, 7:23 PM EDT
Spyre Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts that cover Spyre Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $57.6, which forecasts a 158.99% increase in the stock price over the next year. The lowest target is $43 and the highest is $70.
Price Target: $57.6 (+158.99%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Spyre Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 3 | 3 |
| Buy | 5 | 5 | 5 | 5 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Deutsche Bank | Deutsche Bank | Strong Buy Initiates $43 | Strong Buy | Initiates | $43 | +93.35% | Sep 26, 2025 |
| BTIG | BTIG | Strong Buy Reiterates $70 | Strong Buy | Reiterates | $70 | +214.75% | Sep 16, 2025 |
| Leerink Partners | Leerink Partners | Buy Initiates $45 | Buy | Initiates | $45 | +102.34% | Apr 8, 2025 |
| Jones Trading | Jones Trading | Hold Initiates n/a | Hold | Initiates | n/a | n/a | Dec 11, 2024 |
| Baird | Baird | Buy Maintains $50 → $65 | Buy | Maintains | $50 → $65 | +192.27% | Nov 13, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-2.93
from -3.18
EPS Next Year
-3.36
from -2.93
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | n/a | |||
| Avg | n/a | n/a | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.42 | -2.61 | |||
| Avg | -2.93 | -3.36 | |||
| Low | -3.43 | -4.12 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.